These benefits make oral semaglutide a valuable tool for sustainable weight management and improving overall health in the long run
About this article Cite this article Xu, Y., Boyle, T.A., Lyu, B
So far, the trials seem to show: high reduction in weight, hovering around 28% for those on a 12-milligram dose self-reported improvements in cardiometabolic risk factors like high blood pressure, insulin, and fasting glucose promising results for type 2 diabetes and fatty liver disease a reduction in pain from knee osteoarthritis Retatrutide may be valuable for those who have had limited success with other weight loss drugs, have a higher BMI, or are at significant metabolic risk
Suspected adverse reactions can be reported to the MHRA Yellow Card Scheme
Last updated December 2025
Of course we cant know if this imposed reduced frequency had any impact however the word pernicious springs to mind